COEP vs. CHRO, TVGN, GENE, BCDA, ONVO, IKT, SNTI, PMCB, SRNE, and AIM
Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Chromocell Therapeutics (CHRO), Tevogen Bio (TVGN), Genetic Technologies (GENE), BioCardia (BCDA), Organovo (ONVO), Inhibikase Therapeutics (IKT), Senti Biosciences (SNTI), PharmaCyte Biotech (PMCB), Sorrento Therapeutics (SRNE), and AIM ImmunoTech (AIM). These companies are all part of the "biological products, except diagnostic" industry.
Coeptis Therapeutics (NASDAQ:COEP) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment.
Chromocell Therapeutics has lower revenue, but higher earnings than Coeptis Therapeutics.
Coeptis Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 756.90%. Given Coeptis Therapeutics' higher possible upside, research analysts plainly believe Coeptis Therapeutics is more favorable than Chromocell Therapeutics.
In the previous week, Chromocell Therapeutics had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 2 mentions for Chromocell Therapeutics and 1 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.69 equaled Chromocell Therapeutics'average media sentiment score.
Chromocell Therapeutics' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.
Coeptis Therapeutics received 5 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users.
13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Coeptis Therapeutics beats Chromocell Therapeutics on 5 of the 9 factors compared between the two stocks.
Get Coeptis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coeptis Therapeutics Competitors List
Related Companies and Tools
